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ABSTRACT
This article seeks to demonstrate that health equity, as an empirical and
normative concept, is reflected in the human rights to health and equality
under international law. The obligations on government that flow from health
equity as a human right are then examined. These include the obligation to act
in pursuit of health equity as a policy objective, and the obligation to enact
measures to ensure health equity as a policy outcome. These obligations are
considered in relation to a promising remedial measure for social disparities
in cervical cancer: HPV vaccines.
INTRODUCTION
Cervical cancer is widely referred to as a striking and tragic case of health
inequity.1 There is no shortage of scientific knowledge or technical
intervention. Cervical cancer is preventable and treatable through existing
measures. These measures have dramatically decreased cervical cancer
incidence and mortality, but their benefits have been unequally distributed
within and across countries.
While cervical cancer rates have drastically fallen in developed countries
due to effective prevention and treatment, socially disadvantaged women
†
B.A., J.D., University of Toronto; LL.M., Harvard Law School. Co-Director,
International Reproductive and Sexual Health Law Programme, Faculty of Law, University of
Toronto.
1
See, e.g., Jan M. Agosti & Sue J. Goldie, Introducing HPV Vaccine in Developing
Countries — Key Challenges and Issues, 356 New Eng. J. Med. 1908, 1908 (2007); Silvina
Arrossi et al., Social Inequality in Pap Smear Coverage: Identifying Under-Users of Cervical
Cancer Screening in Argentina, 16 Reproductive Health Matters 50, 50 (2008); Sue J.
Goldie et al., Health and Economic Outcomes of HPV 16, 18 Vaccination in 72 GAVI-Eligible
Countries, 26 Vaccine 4080, 4080 (2008); A.E. Pollack et al., Cervical Cancer: A Call for
Political Will, 94 Int’l. J. Gynecology & Obstetrics 333, 333 (2006); Vivien Tsu & Carol
Levin, Making the Case for Cervical Cancer Prevention: What About Equity?, 16
Reproductive Health Matters 104, 104 (2008); Scott Wittet & Vivien Tsu, Cervical Cancer
Prevention and the Millennium Development Goals, 86 Bull. World Health Org. 488, 488
(2008).
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within these countries remain disproportionately more likely to develop and
die of cervical cancer.2 In most developing countries, in contrast, cervical
cancer rates have risen or remained unchanged.3 More than eighty-three
percent of the 493,000 incident cases of cervical cancer, and an even higher
proportion of the 273,000 related annual deaths, occur in the developing
countries of sub-Saharan Africa, Latin America and the Caribbean, South and
South-East Asia, and Melanesia.4 Cervical cancer is the primary cause of
cancer-related deaths5 and years of life lost6 among women in developing
countries. These women are more likely to be diagnosed with late-stage
disease, receive either no treatment or treatment that does not meet currently
accepted standards of care, and suffer without the benefit of pain control and
other palliative care.7 These social disparities in prevention, incidence,
detection, treatment, and survival are avoidable, but are not avoided. For
these reasons, cervical cancer is a health inequity.
The conceptualization of cervical cancer as a health inequity grounds
ethical claims of injustice and political demands for action.8 The health
inequity of cervical cancer also suggests a legal claim. This article seeks to
articulate this legal claim under international human rights law.
Part I examines the reflection of health equity as an empirical and
normative concept in the human rights to health and equality. Given health
equity as a human right, social disparities in cervical cancer are reconceived as
a violation of international human rights law.
Part II focuses on the legal obligations of government that flow from
health equity as a human right, and social health disparities as a human rights
violation.9 These obligations, broadly phrased, include the obligation to act in
pursuit of health equity as a policy objective, and the obligation to enact
measures to ensure health equity as a policy outcome. Part II considers these
obligations in relation to a promising remedial measure for cervical cancer
inequity: HPV vaccines.
While international law cannot itself remedy social disparities in cervical
cancer, the framing of health equity as a human right may strengthen the
normative commitment to ensure government action in pursuit of this goal.

2
World Health Org., Comprehensive Cervical Cancer Control: A Guide to
Essential Practice 18 (2005).
3
Id.
4
J. Ferlay et al., Int’l Agency for Research on Cancer, GLOBOCAN 2002:
Cancer Incidence, Mortality and Prevalence Worldwide (2004), http://wwwdep.iarc.fr/; D. Max Parkinet al., Global Cancer Statistics, 2002, 55 CA Cancer J. Clinicians
74, 78 (2005).
5
See supra note 4.
6
D. Maxwell Parkin & Freddie Bray, Chapter 2: The Burden of HPV-Related Cancers,
21 Vaccine S3/11, S3/12 (2006).
7
Nancy Krieger, Defining and Investigating Social Disparities in Cancer: Critical
Issues, 16 Cancer Causes & Controls 5, 5 (2005).
8
See supra note 1.
9
While human rights obligations attach to all members of society, including
individuals, the private business sector, intergovernmental and non-governmental actors, this
article limits its analysis to considerations of the human rights obligations attaching to
government.
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HEALTH EQUITY AS A HUMAN RIGHT

A. The Empirical and Normative Dimensions of Health Equity
Health equity has a range of theoretical backgrounds and definitions.10
Margaret Whitehead’s 1992 formulation remains a standard working
definition of the term.11 Health inequity refers to “differences in health that
are not only unnecessary and avoidable, but in addition unfair and unjust.”12
Subsequent iterations retain the empirical and normative dimensions of
health equity, but modify their relationships. Health inequity refers to health
disparities that are unjust because they are avoidable and thus unnecessary.13
This definition raises questions of fact and value: whether differences in
health are avoidable and thus unnecessary, and why are such differences
unjust.
Paula Braveman and Sofia Gruskin answer these questions by focusing on
social disadvantage as a key feature of health inequity.14 While Whitehead
does not explicitly use the term “disadvantaged” in her definition, Braveman
explains that Whitehead intended to refer to differences that adversely affect
“disadvantaged nations and groups” as implied by her examples.15
Health inequity, Braveman argues, is identified by the systematic tracking
of health disparities with the social hierarchy, which consists of the different
relative positions of social advantage and disadvantage as defined by, for
example, gender, race, ethnicity, wealth, income, education, occupation, and
geographic residence.16 Social groups who have persistently experienced social
disadvantage or discrimination in the past systematically experience greater
health risk and worse health outcomes than the most advantaged social
groups.17 Health inequity thus refers to health disparities between social
groups categorized by some important feature of their underlying social
position,18 social health disparities in short.

10
A.J. Culyer & Adam Wagstaff, Equity and Equality in Health and Health Care, 12 J.
Health Econ. 431, 432 (1993); Anthony J. Culyer, Equity - Some Theory and its Policy
Implications, 27 J. Med. Ethics 275, 275 (2001).
11
Margaret Whitehead, The Concepts and Principles of Equity in Health, 22 Int’l J.
Health Services 429 (1992).
12
Id. at 431.
13
This concept tracks the general principle of horizontal equity insofar as avoidable
and unnecessary differences suggest that the disparities in health status are capricious or
related to irrelevant characteristics. Culyer, supra note 10, at 276.
14
Paula Braveman, Health Disparities and Health Equity: Concepts and Measurement,
27 Ann. Rev. Pub. Health 167, 167 (2006) [hereinafter Braveman, Health Disparities];
Paula A. Braveman, Monitoring Equity in Health and Healthcare: A Conceptual Framework,
21 J. Health, Population, & Nutrition 181, 181 (2003) [hereinafter Braveman, Monitoring
Equity]; P. Braveman & S. Gruskin, Defining Equity in Health, 57 J. Epidemiology &
Community Health 254, 254 (2003) [hereinafter Braveman & Gruskin, Defining Equity];
Paula Braveman & Sofia Gruskin, Poverty, Equity, Human Rights and Health, 81 Bull.
World Health Org. 539, 539 (2003) [hereinafter Braveman & Gruskin, Poverty].
15
Braveman, Health Disparities, supra note 12, at 168.
16
Braveman, Monitoring Equity, supra note 12, at 181; Braveman & Gruskin, Defining
Equity, supra note 12, at 254.
17
Braveman, Monitoring Equity, supra note 12, at 181.
18
Id. at 182.
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According to this definition, cervical cancer is a striking case of health
inequity. Women belonging to disadvantaged social groups are
disproportionately more likely to develop and die of cervical cancer across and
within countries. The vast majority of the incident cases of cervical cancer
and related deaths annually occur in developing countries. 19 Cervical cancer is
the primary cause of cancer-related deaths and years of life lost among women
in these countries.20 Within all countries, cervical cancer disparities track
indicators of underlying social position. A meta-analysis of fifty-seven studies
revealed an increased risk of approximately 100 percent between high and low
social class categories for the development of invasive cervical cancer.21 This
increased risk was apparent in all geographic regions, although it was stronger
in Africa, Asia and Latin America and the Caribbean than in Europe.22 These
measures of cervical cancer disparities, moreover, may be underrepresented
given misclassification and underreporting along indicators of social
disadvantage in the data itself.23 Cervical cancer inequity cannot be effectively
decreased without improving the information systems necessary to measure
disparities and monitor progress.
What renders social health disparities avoidable and thus unnecessary?
The answer lies in their cause. Causes of social health disparities are complex
and multifactorial, with epidemiology rarely able to establish relationships
between cause and effect. The systematic association of greater health risk
and worse health outcomes with social disadvantage – the association being
significant, frequent or persistent rather than random or occasional24 –
nevertheless allows for a plausible general inference that social health
disparities are informed by the social hierarchy and the social institutions that
create, maintain and give it force. One such institution is the health system,
which converts the social hierarchy into unequal health resources, access to
services and health outcomes. Health inequity is a function of how
governments distribute health resources and design health programs. 25
The social hierarchy and the health distribution linked to this hierarchy
are thus neither natural nor inevitable. Social health disparities result from
an avoidable and unnecessary determinant: government action. Braveman
explicitly defines health inequity as “a particular type of potentially avoidable

19

See, sources cited supra note 4.
See, sources cited supra notes 4, 6.
Seema Parikh et al., Meta-Analysis of Social Inequality and the Risk of Cervical
Cancer, 105 Int’l J. Cancer 687, 688 (2003).
22
Id.
23
See id. at 687; see also Pollack et al., supra note 1, at 334 (noting that underreporting
may result from an emphasis on maternal heath that prejudices older women); Rose Anorlu,
Cervical Cancer: the sub-Saharan African Perspective, 16 Reproductive Health Matters
41, 42 (2008) (noting that underreporting is common in many areas of Africa); Emmanuela
Gakidou et al., Coverage of Cervical Cancer Screening in 57 Countries: Low Average Levels and
Large Inequalities, 5 Plos Med. 0864, 0867 (2008) (describing general problems with
underreporting).
24
Barbara Starfield, Improving Equity in Health: A Research Agenda, Int’l J. Health
Services 545, 547 (2001); Braveman, Health Disparities, supra note 14, at 171.
25
See Braveman, Monitoring Equity, supra note 12, at 188-90 (noting that equity is a
matter of distributive justice); Braveman & Gruskin, Defining Equity, supra note 12, at 257
(noting that equity depends on the distribution and design of resources, policies, and
programmes).
20
21
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difference in health or in important influences on health that can be shaped
by policies.” 26
Preventable diseases warrant a comment in relation to the criteria of
avoidable and unnecessary. It is suggested that health equity is of particular
relevance to diseases, such as cervical cancer, where there is no shortage of
scientific knowledge or technical intervention to prevent the disease.27
Preventable diseases are analytically valuable insofar as they indicate what is
theoretically attainable, and therefore set a minimum standard for what is
potentially avoidable through government action.28 Braveman is careful to
note, however, that empiric evidence of avoidability in this sense should not
be a prerequisite for a health disparity to qualify as a health inequity.29 The
unavailability of prevention measures may itself, for example, be a
consequence of government action.
Cervical cancer is a preventable disease, a characteristic relevant to the
characterization of social disparities in cervical cancer as avoidable and
unnecessary. The prevention of cervical cancer is based on the discovery that
infection with one or more high-risk types of the human papillomavirus
(“HPV”) is a necessary cause of cervical cancer.30 HPV infection is a highly
prevalent sexually transmitted infection. Most women will be infected with
HPV during their lifetime, with high rates in young women following sexual
debut.31 While most infections are asymptomatic and transient, persistent or
chronic infection over decades with a high-risk HPV type is associated with
pre-cancerous lesions of the cervix that may progress to cervical cancer.32
Several factors are associated with increased risk of both initial infection
with high-risk HPV types and developing cervical cancer once infected.
Individual level factors include both biological factors (e.g. coinfection with
other sexually transmitted agents and immunodeficiency) and behavioral
factors (e.g. nonuse of condoms, multiple sexual partners,33 young age at
sexual debut).34
While differences in individual level factors may have some effect on
social disparities in cervical cancer,35 they are not considered the dominant
cause of the social distribution. The most important determinant of social
26
Braveman, Health Disparities, supra note 12, at 180. See also Braveman & Gruskin
Poverty, supra note 12, at 540 (noting that government should seek to address health
inequities not only through health policy, but through policy addressing the underlying
conditions of social disadvantage, such as education, living standards and environment).
27
Pollack et al., supra note 1, at 337.
28
See generally Braveman & Gruskin, Defining Equity, supra note 12, at 255, for a
discussion of avoidability in relation to health equity.
29
Braveman, Health Disparities, supra note 14, at 185.
30
J.M. Walboomers et al., Human Papillomavirus is a Necessary Cause of Invasive
Cervical Cancer Worldwide, 189 J. Pathology 12, 18 (1999); Nubia Muñoz et al., Chapter
1:HPV in the Etiology of Human Cancer, 24S3 Vaccine S3/1, S3/1 (2006).
31
F. Xavier Bosch et al., Epidemiology and Natural History of Human Papillomavirus
Infections and Type-Specific Implications in Cervical Neoplasia, 26S Vaccine K1, K2 (2008).
32
M. Stanley, Immune responses to human papillomavirus, 24S1 Vaccine 16 (2006).
33
This factor also includes the sexual behaviour of male partners. Women but not their
male partners, for example, may be monogamous. Maribel Almonte, Risk factors for Human
Papillomavirus Exposure and Co-Factors for Cervical Cancer in Latin America and the
Caribbean, 26S Vaccine L16, L24 (2008).
34
World Health Org., supra note 2, at 35.
35
See, e.g., Parikh et al., supra note 19, at 689.
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disparities in cervical cancer is a health systems factor shaped by government
action: social disparities in access to prevention measures, namely cervical
screening.36
Cervical screening allows for the early detection, follow-up and treatment
of precancerous cervical abnormalities.37 It is a viable and highly effective
prevention strategy because of the prolonged progression from infection to
disease.38
In countries that have implemented high-quality screening
programs using the Papanicolaou cytology method, societal average cervical
cancer incidence and mortality rates have dramatically decreased.39 These
drastic reductions indicate the standard of health theoretically attainable
among socially disadvantaged women, setting a minimum standard for what
is possible through government action.
Central to health equity is thus not the association of health distribution
with the social hierarchy, nor the fact of existing prevention measures, but the
capacity of government to change the social hierarchy or to modify its effects
on the distribution of health risks and outcomes. There are important reasons
to empirically locate the cause of social health disparities in government
action, among them, providing an explanation why social health disparities
are unjust, the normative dimension of health equity.
Social health disparities are unjust, according to Braveman and Gruskin,
because they result from government action that adversely affects the health
risks and outcomes of groups already disadvantaged by virtue of their
underlying social position.40 Social health disparities result from government
action that places already disadvantaged social groups at further disadvantage
with respect to their health.41 For this reason, social health disparities violate
ethical principles of distributive justice.42 These principles are widely
interpreted to require that priority be given to improving the situation of the
socially disadvantaged.43
B. Health Equity in International Human Rights Law
The empirical and normative dimensions of health equity – government
action and distributive justice – support an additional claim of injustice
grounded not in ethics or politics but in law. These dimensions of health
equity are reflected in the human rights to health and equality. Health

36

Id.; Lynette Denny, Prevention of Cervical Cancer, 16 Reproductive Health
Matters 18, 19 (2008).
37
R. Sankaranarayanan et al., A Critical Assessment of Screening Methods for Cervical
Neoplasia, 89 Int’l J. Gynecology & Obstetrics S4, S4-5 (2005).
38
Id. at S5; Lynette Denny, The Prevention of Cervical Cancer in Developing Countries,
112 BJOG: Int’l J. Obstetrics & Gynaecology 1204, 1204 (2005).
39
World Health Org., supra note 2, at 18; Gakidou, supra note 23, at 0863.
40
Braveman & Gruskin, Defining Equity, supra note 14, at 256; Braveman, Health
Disparities, supra note 14, at 185.
41
Braveman & Gruskin, Defining Equity, supra note 14, at 254; Braveman, Health
Disparities, supra note 14, at 182.
42
Braveman, Monitoring Equity, supra note 14, at 189.
43
In the literature, the principle of distributive justice that priority be given to the
least advantaged in society is often referenced to the work of political philosopher John Rawls.
See, e.g., Braveman, Health Disparities, supra note 14, at 183; W-C Chang, The Meaning and
Goals of Equity in Health, 56 J. Epidemiology & Community Health 488, 489 (2002).
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inequity, including social disparities in cervical cancer, may thus be
reconceived as a human rights violation.
International human rights law, based on a series of conventions to which
States parties voluntarily adhere, reflects legally enforceable standards of
government action that have their origins in ethical values.44 Given this
relationship, Braveman and Gruskin, among others, support the normative
foundation of health equity by reference to both ethical principles and human
rights.45 The human rights to health and equality support the proposition that
social health disparities are unjust.
The right to health is protected in several international and regional
human rights conventions. Its content and meaning are most fully articulated
with respect to Article 12 of the International Covenant on Economic, Social
and Cultural Rights (“CESCR”),46 which requires that States parties
“recognize the right of everyone to the enjoyment of the highest attainable
standard of physical and mental health.”47 The right to health is closely
related to and dependent upon the realization of other human rights,
including rights to equality and non-discrimination.48 Under CESCR, States
parties undertake to guarantee that the right to health will be exercised
without discrimination of any kind, and in particular, on the basis of sex and
gender.49 The Convention on the Elimination of All Forms of Discrimination
against Women (“CEDAW”) expressly addresses equality in health care on
these grounds.50 Article 12 of CEDAW requires “States Parties . . . [to] take all
appropriate measures to eliminate discrimination against women in the field
of health care in order to ensure, on a basis of equality of men and women,
access to health care services.”51
While many other international human rights conventions are relevant to
the conceptualization of health equity as a human right, the analysis in this
article is limited to the right to health and the right to equality in CESCR and
CEDAW, and their related commentary.52 Emphasis will be placed on General
Comment No. 14: the Right to the Highest Attainable Standard of Health

44
Rebecca J. Cook et al., Reproductive Health and Human Rights: Integrating
Medicine, Ethics, and Law 151 (2003).
45
Braveman, Health Disparities, supra note 14, at 183; Braveman & Gruskin, Defining
Equity, supra note 14, at 255; Braveman & Gruskin, Poverty, supra note 14, at 540.
46
International Covenant on Economic, Social and Cultural Rights, Dec. 16, 1966, 993
U.N.T.S. 3, (entered into force Jan. 3, 1976) [hereinafter CESCR].
47
Id. art. 12(1).
48
In this article, the term “right to equality” refers to both the right to equality and the
right to non-discrimination.
49
CESCR, supra note 46, arts. 2.2, 3.
50
Convention on the Elimination of All Forms of Discrimination against Women art.
12, Dec. 18, 1979, 1249 U.N.T.S. 13 (entered into force Sept. 3, 1981).
51
Id. art. 12(1).
52
U.N. bodies that monitor States parties’ compliance with international human rights
conventions issue General Comments or General Recommendations, which are authoritative
commentary on aspects related to specific articles in the conventions. This commentary is
intended to assist States parties in complying with their obligations under the Conventions.
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(“General Comment No. 14”)53 and General Recommendation No. 24: Women
and Health (“General Recommendation No. 24”).54
Braveman and Gruskin assert that the right to health can be
“operationalized as the right of all social groups . . . to attain the level of health
enjoyed by the most privileged group in society.”55 This interpretation of the
right to health, which can be extended to the right to equality, is well
supported.
The right to health, as explained in General Comment No. 14, is not
understood as a right to be healthy.56 Differences in health status are not in
themselves a human rights violation. Akin to the concept of health equity, the
right to health concerns the systematic association of health disparities with
underlying social advantage and disadvantage. Informed by the social
hierarchy, these health disparities are created, maintained and given force by
government action, including the design and implementation of health
systems.
The right to health is defined in part as an entitlement to a “system of
health protection which provides equality of opportunity for people to enjoy
the highest attainable level of health.”57 Government action which converts
underlying social position into unequal health resources, services and
outcomes – a system which places already disadvantaged groups at further
disadvantage with respect to their health – violates the right to health.
General Recommendation No. 24, developed in reference to Article 12 of
CEDAW, nicely captures this aspect of the right to health as related to the
right to equality:
Studies such as those which emphasize the high maternal
mortality and morbidity rates worldwide . . . provide an
important indication for States parties of possible breaches of
their [human rights] duties . . . . States parties [are] to report on
what they have done to address the magnitude of women's illhealth, in particular when it arises from preventable conditions
. . . . States parties should therefore report on what they have
done to organize governmental processes and all structures
through which public power is exercised to promote and protect
women's health.58
Central to the rights to health and equality is thus government action –
including all structures and processes through which public power is exercised
53
U.N. Comm. on Econ., Soc. and Cultural Rights, General Comment No. 14. The Right
to the Highest Attainable Standard of Health, UN doc E/C.12/2000/4 (Aug. 11, 2000)
[hereinafter General Comment No. 14].
54
U.N. Comm. on the Elimination of all Forms of Discrimination against Women,
General Recommendation No. 24: Women and Health, UN Doc. A/54/38/Rev.1 (1999)
[hereinafter General Recommendation No. 24].
55
Braveman, Health Disparities, supra note 14, at 184; see also Braveman & Gruskin
Defining Equity, supra note 14, at 254.
56
General Comment No. 14, supra note 53, ¶ 7. “There are a number of aspects which
cannot be addressed solely within the relationship between States and individuals; in
particular, good health cannot be ensured by a State, nor can States provide protection against
every possible cause of human ill health.” Id. ¶ 9.
57
Id. ¶ 8 (emphasis added).
58
General Recommendation No. 24, supra note 54, ¶ 17 (emphasis added).
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– that seeks to modify the adverse distributive effects of underlying social
position on health risks and outcomes, and to thus protect and promote the
highest attainable standard of health among the socially disadvantaged.59
These principles of distributive justice are reflected in the interrelated and
essential elements of the right to health: availability, accessibility,
acceptability and quality.60 Functioning public health programs as well as
medically appropriate and good quality health facilities, goods and services
are to be sufficiently available to meet health needs.61 The elements of
accessibility and acceptability, in particular, require selective concern for the
vulnerable and marginalized. The right to health under CESCR requires that
“health facilities, goods and services must be accessible to all, especially the
most vulnerable or marginalized sections of the population, in law and in fact,
without discrimination.”62 Facilities, goods and services must therefore “be
within safe physical reach for all sections of the population, especially
vulnerable or marginalized groups, such as ethnic minorities and indigenous
populations, women . . . including in rural areas.”63 Whether provided
privately or publicly, services should be economically accessible, and
“affordable for all, including socially disadvantaged groups.”64 Acceptable
health facilities, goods and services must also be “respectful of the culture of
individuals, minorities, peoples and communities, sensitive to gender and lifecycle requirements . . . [and designed to] improve the health status of those
concerned.”65
Attention to underlying social disadvantage is also an essential feature of
the right to equality. Government cannot enact a health system that places
already disadvantaged groups at further disadvantage with respect to health
whether by design or effect. General Comment No. 14 explicitly notes that
[i]nappropriate health resource allocation can lead to
discrimination that may not be overt. For example, investments
should not disproportionately favour expensive curative health
services which are often accessible only to a small, privileged
fraction of the population, rather than primary and preventive
health care benefiting a far larger part of the population.66
The facial neutrality of a health policy or program, government disregard
for the adverse effects of underlying social disadvantage, may constitute
discrimination. Government thus cannot enact a health system for the benefit
of the general population without ensuring that disadvantaged social groups
can enjoy the full benefits of the system. This selective concern for the socially
disadvantaged applies to all aspects of the health system.
Articles 2.2 and 3 of CESCR, for example, proscribe any discrimination in
access to health care, including the “means and entitlements for their
procurement . . . which [have] the intention or effect of nullifying or
59
60
61
62
63
64
65
66

General Comment No. 14, supra note 53, ¶ 9.
Id. ¶ 12.
Id. ¶ 12(a) and (d).
Id. ¶ 12(b).
Id.
Id.
Id. ¶ 12(c).
Id. ¶ 19.
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impairing the equal enjoyment or exercise of the right to health.”67 These
Articles support the interpretation that the right to health imposes a special
obligation on government to “provide those who do not have sufficient means
with the necessary health insurance and health-care facilities.”68
General Recommendation No. 24 draws particular attention to “societal
factors which are determinative of the health status of women . . . [and] which
can vary among women themselves . . . . [S]pecial attention should be given to
the health needs and rights of women belonging to vulnerable and
disadvantaged groups.”69 Acceptable health services are defined as services
“delivered in a way that ensures that a woman gives her fully informed
consent, respects her dignity, guarantees her confidentiality and is sensitive to
her needs and perspectives.”70
Conventional prevention measures in cervical cancer, namely screening
programs, fail to reflect these human rights standards. There is an acute
shortage of functional screening programs in most developing countries,71 and
widespread failure to account for underlying factors that render screening less
or inaccessible to socially disadvantaged women within countries.72
Screening programs in most developing countries are insufficiently
available and of poor quality, which results in much lower screening
coverage73 and contributes to higher cervical cancer incidence and mortality.74
Screening coverage in developing countries is, on average, nineteen percent
compared to sixty-three percent in developed countries.75 “In women who
have never been screened, cancer tends to be diagnosed in its later stages,
when it is less easily treatable,” which leads to increased rates of mortality.76
In countries with screening programs, disadvantaged social groups are
disproportionately represented among the unscreened and the untreated.77
Indigenous women in Latin America have lower screening utilization rates
than societal averages.78 In South Africa, cervical cancer disparities between
race groups, urban and rural residence, and high and low wealth status is
attributed to disparate screening coverage.79
67

Id. ¶ 18.
Id. ¶ 19; see also General Recommendation No. 24, supra note 54, ¶ 22.
69
General Recommendation No. 24, supra note 54, ¶¶ 6, 12(b).
70
Id. ¶ 22.
71
Gakidou et al., supra note 23, at 0864.
72
Id. at 0865.
73
The term “coverage” refers to “the proportion of women in the target age group who
are screened at the recommended intervals during a given time period. The number of
screening tests done is not coverage, since this number may include women outside the target
age, and women screened more often than recommended.” World Health Org., supra note 2, at
83.
74
Id. at 18; Lynette Denny et al., Screening for Cervical Cancer in Developing
Countries, 24S3 Vaccine S3/71, S3/71-72 (2006).
75
Gakidou et al., supra note 23, at 0863.
76
World Health Org., supra note 2, at 16.
77
See, e.g., Arrossi & Goldie, supra note 1, at 51; Denny, supra note 36, at 19.
78
See Silvana Luciani & Jon Kim Andrus, A Pan American Health Organization
Strategy for Cervical Cancer Prevention and Control in Latin America and the Caribbean, 16
Reproductive Health Matters 59, 64 (2008) (Stating the utilization rates for indigenous
women).
79
Mary Kawonga & Sharon Fonn, Achieving Effective Cervical Screening Coverage in
South Africa through Human Resources and Health Systems Development, 16 Reproductive
Health Matters 32, 32-33 (2008).
68
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Social disparities in demand and utilization result from government
failure to ensure screening programs are accessible and acceptable to all.
Programs are implemented without sufficient attention to the conditions that
render screening less or inaccessible to disadvantaged social groups,
including: lack of information, undervaluing of preventive care, opportunistic
delivery in limited health care settings, sexual health stigma and related
privacy concerns.
Information
is
an
important
dimension
of
accessibility.80
Underutilization of screening services is commonly attributed to poor
awareness of and information about cervical cancer81 and the benefits of
screening in prevention and early detection.82 Failure to appropriately
distinguish among screening, diagnosis and treatment, for example, may
adversely affect demand for screening.83 A positive HPV test may be mistaken
as a diagnosis of cancer, falsely regarded as an untreatable disease. The
psychological and financial burden of a perceived fatal diagnosis may deter
women from screening. A mistaken understanding of cervical cancer
screening as preventive care can itself be a barrier to access, given the low
priority assigned to asymptomatic screening.84 Economic barriers and social
norms contribute to the undervaluing of preventive care. Given that screening
does not provide any immediate health benefit, its value may be discounted
and deemed insufficient to warrant expenditure of scarce private resources.
Cost sharing, for example, has a significant adverse effect on social disparities
in preventive care.85 In Latin America and the Caribbean, health insurance,
an indicator of social advantage, is positively associated with cervical cancer
screening among older women.86 Gender and age may exacerbate economic
barriers. Within the household, social norms may favor expenditure on health
services for males over females, and the young over the old.87
Cervical screening is often opportunistic, offered by providers to relatively
young women who attend family planning, antenatal and child health
clinics.88 Restricting screening services to clinic facilities disadvantages rural
women, whose physical access to institutional healthcare is often restricted to
health emergencies.89 In Latin America, for example, “transportation costs
and distance played a significant role in access to screening services. Rates

80
General Comment No. 14, supra note 53, ¶ 12(b); see also N. Wellensiek et al.,
Knowledge of Cervical Cancer Screening and Use of Cervical Screening Facilities among
Women from Various Socioeconomic Backgrounds in Durban, Kwazulu Natal, South Africa, 12
Int’l J. Gynecological Cancer 376, 377 (2002).
81
World Health Org., supra note 2, at 20.
82
J. Bradley et al., Widening the Cervical Cancer Screening Net in a South African
Township: Who are the Underserved?, 25 Health Care Women Int’l 227, 238 (2004).
83
V. Lorant et al., Equity in Prevention and Health Care, 56 J. Epidemiology &
Community Health 510, 515 (2002).
84
Id.
85
Id. at 514-15.
86
Carlos A. Reyes-Ortiz et al., Health Insurance and Cervical Cancer Screening Among
Older Women in Latin American and Caribbean Cities, 37 Int’l J. Epidemiology 870, 874-76
(2008).
87
Tsu & Levin, supra note 1, at 105, 107.
88
World Health Org., supra note 2, at 84.
89
Pollack, supra note 1, at 334.
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were much higher where clinics were more accessible or where mobile clinics
brought services to women.”90
The limited availability of cervical cancer screening in family planning,
antenatal and child care clinics also disadvantages older women, who are at
the greatest health risk but least likely to be screened.91 The association
between HPV, a sexually transmitted infection, and cervical cancer
contributes to this bias. The reproductive and sexual health of older women is
often undervalued.92 Older women themselves undervalue their health needs,
accepting “the physical discomforts associated with gynecological problems,
menopause, and ageing as natural.”93 Women at the end of their reproductive
years are less likely to seek family planning, antenatal and child care services,
and opportunistic screening is seldom provided in health facilities where older
women are more likely to seek services, such as management of hypertension,
heart disease, and diabetes.94
The association of screening programs with a sexual transmitted infection
poses a further social barrier to access. There is a stigma related to diseases of
the reproductive tract, particularly sexually transmitted infections such as
HPV. General Recommendation No. 24 emphasizes guaranteed
confidentiality as an important determinant of accessible and acceptable care,
in particular respecting sexual health services: “lack of respect for the
confidentiality . . . may deter women from seeking advice and treatment and
thereby adversely affect their health and well-being. Women will be less
willing, for that reason, to seek medical care for diseases of the genital tract
. . . .”95 Fear and embarrassment of genital examinations, association with a
sexually transmitted infection, and lack of confidentiality adversely affect
screening demand and utilization.96 In rural Mexico, for example, anxiety
regarding physical privacy was the most frequent reason for not seeking or
delaying screening.97 Women may also be uncomfortable seeking and
receiving screening from male health care providers, yet female providers are
underrepresented in the health system.98
Health systems, in the design and implementation of cervical cancer
screening programs, may thus place socially disadvantaged women at further
disadvantage with respect to their health. Cervical cancer inequity, for this
reason, violates the rights to health and equality under international law.
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II. THE OBLIGATIONS OF HEALTH EQUITY AS A HUMAN RIGHT
Human rights ground health equity as a normative concept and are
principally used to this effect in the literature. Social health disparities are
unjust because they result from government action in violation of the rights to
health and equality. International human rights law, however, offers more
than an additional claim of injustice. As a formal body of law, its strength
resides in the attachment of legal obligations and accountability to the
injustice of health inequity.99 Health inequity by law rather than by ethics,
charity or good practice requires remedial government action. International
human rights law legally obligates governments of States parties to account
for and to remedy social health disparities, and provides the practical basis for
policy-making in pursuit of this objective.
Part II of the article focuses on the legal obligations of government that
flow from health equity as a human right. These obligations, broadly phrased,
include the obligation to act in pursuit of health equity as a policy objective,
and the obligation to enact measures to ensure health equity as a policy
outcome. Both obligations are considered in relation to a particularly
promising remedial measure for cervical cancer inequity: HPV vaccines.
Conventional cytology-based HPV screening programs require a strong
health infrastructure, sophisticated equipment, and technical expertise.100
These programs are widely held to be beyond the capacity of many developing
countries given limited human and financial resources and weak
infrastructures.101
The claim that conventional screening programs cannot be implemented
must be distinguished from a claim that government cannot reduce social
disparities in cervical cancer. The right to health requires government to take
whatever steps are necessary to the maximum of its available resources and by
all appropriate means to reduce health inequities.102 General Comment No. 14
nevertheless acknowledges that the most appropriate measures to implement
the right to health will vary from one jurisdiction to another: “Every State has
a margin of discretion in assessing which measures are most suitable to meet
its specific circumstances.”103 The question asked of governments under
international human rights law is thus whether alternative cervical cancer
prevention measures, more suitable to meeting the needs of socially
disadvantaged women, can be implemented. Two such alternative measures
are low-technology non-cytologic screening methods and HPV vaccines.104
Non-cytologic screening methods including visual inspection screening
and “screen-and-treat” approaches are regarded as promising measures to

99
Braveman & Gruskin, Poverty, supra note 14, at 541. General Comment No. 14
further notes that the right to health includes certain components which are legally
enforceable in national jurisdictions through domestic law including constitutional rights to
equality and non-discrimination. General Comment No. 14, supra note 53, ¶ 1.
100
Denny et al., supra note 82, at S3/71-72.
101
See, e.g., Denny et al., supra note 36, at 18.
102
CESCR, supra note 4, art. 2.1; General Comment No. 14, supra note 53, ¶ 53.
103
General Comment No. 14, supra note 53, ¶ 53.
104
A.E. Pollack and V.D. Tsu, Preventing Cervical Cancer in Low-Resource Settings:
Building a Case for the Possible, 89 Int’l J. Gynecology & Obstetrics S1, S1 (2005).
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reduce cervical cancer inequity.105 These simpler and less expensive screening
measures do not depend on a sophisticated health infrastructure, require
modest equipment, and can be used at the primary health care level by a range
of health providers in urban and rural settings.106 Studies show that
alternative screening methods can reduce global incidence of cervical cancer
by as much as fifty percent.107 Countries in Africa, Asia and Latin America
have allocated government funding to support alternative screening
approaches and have incorporated visual inspection methods into national
cancer guidelines.108
A second and complementary alternative measure focuses on the primary
prevention of cervical cancer: HPV vaccines. The two vaccines developed to
date are highly effective in preventing infection with two high-risk HPV types,
which cause appropriately seventy percent of cervical cancer.109 The vaccines
are most effective prior to initial infection and thus sexual debut, and have
therefore been recommended for priority administration among young
adolescent women.110 Vaccines may place considerably fewer demands on
health systems than screening, utilizing established infrastructure, logistics
networks and information systems of immunization service delivery.111
Studies indicate that HPV vaccines, if made available and accessible to
adolescent women in developing countries, can prevent almost four million
cervical cancer deaths in the next decade.112
The mere opportunity of these prevention measures to remedy cervical
cancer inequity does not guarantee they will be used to this end.
Governments must pursue health equity as a policy objective, and enact
measures to ensure health equity as a policy outcome. The following Sections

105
Denny, supra note 74, at S371; Sue J. Goldie et al., Cost-Effectiveness of CervicalCancer Screening in Five Developing Countries, 353 N. Eng. J. Med. 2158, 2158 (2005);
Sankaranarayanan et al., supra note 42, at S8 (2005).
106
Denny, supra note 74, at S3/73-74.
107
Goldie et al., supra note 105, at 2167.
108
Luciani & Andrus, supra note 78, at 61-62; Tsu & Levin, supra note 1, at 108.
109
Gary Clifford et al., Chapter 3: HPV Type-Distribution in Women with and without
Cervical Neoplastic Diseases, 24S Vaccine S26, S27 (2006).
110
Anna Koulova et al., Country Recommendations on the Inclusion of HPV Vaccines in
National Immunization Programmes among High-Income Countries, June 2006–January
2008, 26 Vaccine 6529, 6534 (2008).
111
F.X. Bosch et al., HPV and Cervical Cancer: Screening or Vaccination?, 98 British
J. Cancer 15, 16 (2008); Mark A. Kane et al., Chapter 15: HPV Vaccine Use in the Developing
World, 24S Vaccine S132, S135 (2006).
112
Sue J. Goldie et al., Benefits, Cost Requirements and Cost-Effectiveness of the HPV 16,
18 Vaccine for Cervical Cancer Prevention in Developing Countries: Policy Implications, 16
Reproductive Health Matters 86, 93 (2008). The projection is based on making an HPV
16, 18 vaccine accessible to 70% of young adolescent girls in the 72 GAVI-eligible countries
(countries with a Gross National Income (GNI) per capita below US $1,000 in 2003) and nonGAVI eligible countries in the Latin American and Caribbean region as well as China and
Thailand. GAVI-eligibility refers to eligibility for technical assistance and financial support
from the GAVI Alliance (formerly the Global Alliance for Vaccines and Immunization), a
partnership of national governments, research and technical health institutes, the World
Health Organization, the World Bank, UNICEF, the Bill & Melinda Gates Foundation, the
vaccine industry, and civil society organizations. Id.
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consider these government actions as human rights obligations in relation to
HPV vaccines.113
A. The Obligation to Act in the Pursuit of Health Equity as a Policy
Objective
The importance of shifting policy objectives to achieve equitable health
outcomes is well-recognized.114 Health policy objectives are often stated in
terms of efficiency and improvement of societal average health status.115 These
objectives, however, can be achieved by improving the health of any social
group, whether advantaged or disadvantaged. Progress toward an increased
average may thus widen social health disparities.
The reorientation of health systems toward health equity requires policy
objectives that prioritize improving the health of the disadvantaged.
International human rights law achieves this reorientation. Health equity is
set as an objective to be taken into account in concert with, and sometimes as
a foil to, other policy objectives in resource allocation and program design.116
Article 12.2 of CESCR references two policy objectives of particular
relevance to health equity.117 The first policy objective is the prevention,
treatment and control of disease.118 The second policy objective is the creation
of conditions that assure to all health facilities, goods and services.119 The
latter objective implicates two core government obligations: to ensure the
right of access to and the equitable distribution of health facilities, goods and
services on a non-discriminatory basis, especially for vulnerable or
marginalized groups.120
General Comment No. 14 emphasizes preventive health care in reference
to both policy objectives. Infectious disease burden disproportionately falls on
disadvantaged social groups. By setting the prevention and control of disease,
including immunization programs, as a policy priority, international human
rights law privileges a health equity objective.121 The control of diseases
requires government efforts to “make available relevant technologies, using
and improving epidemiological surveillance and data collection on a
disaggregated basis.”122 Preventive health services, regular screening
programs, and essential drugs are expressly listed among the health goods and
services to be equitably distributed and accessible on a non-discriminatory
basis.123 These include, moreover, prevention measures “for behaviour-related
113

These obligations and much of the related analysis in Part II can be equally applied
to low-technology non-cytologic screening methods.
114
See Davidson R. Gwatkin et al., Making Health Systems More Equitable, 364 Lancet
1273, 1277 (2004).
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Fatima Alvarez-Castillo et al., Priority Setting, in The Right Reforms? Health
Sector Reforms and Sexual and Reproductive Health 137, 139-140 (T.K. Sundri
Ravindarn & Helen de Pinho eds., 2005).
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Id. 168.
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CESCR, supra note 46, art. 12.2.
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CESCR, supra note 41, art. 12.2(c).
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CESCR, supra note 41, art. 12.2(d).
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General Comment No. 14, supra note 53, ¶ 43(a),(e).
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See FE Andre et al., Vaccination Greatly Reduces Disease, Disability, Death and
Inequity Worldwide, 86 Bull. World Health Org. 140, 143 (2008).
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General Comment No. 14, supra note 53, ¶ 16.
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Id. ¶ 17.
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health concerns such as sexually transmitted diseases, in particular . . . those
adversely affecting sexual and reproductive health.”124 Prioritization of
cervical cancer and HPV vaccines should thus not be affected by their
association with a sexually transmitted infection.
A core obligation under the right to health ensures that societal average
improvements in health status are not the sole objective of prevention
programs. Government is required to adopt and implement a national public
health strategy and plan of action that address the health concerns of the
whole population, but which also “give particular attention to all vulnerable or
marginalized groups.”125 This obligation ensures that an objective of all HPV
vaccination programs is to improve the health status of the socially
disadvantaged, and that progress is monitored in terms of this objective.
The obligation to give particular attention to disadvantaged social groups
is consistent with the more specific requirement of the rights to health and
equality to integrate a gender perspective into all health-related policies.126
These rights require that government abstain “from enforcing discriminatory
practices as a State policy; and . . . from imposing discriminatory practices
relating to women's health status and needs.”127 These discriminatory
practices extend to resource allocation. Government is obligated to ensure
that women’s health receives an equitable share of budgetary, human and
administrative resources, taking into account women’s different health
needs.128 That HPV vaccines target a sex-specific disease – cervical cancer –
should thus not diminish vaccination as a public health priority. On the
contrary, the elimination of discrimination against women requires
“interventions aimed at both the prevention and treatment of diseases
affecting women,” as well as policies to provide access “for all women to a full
range of high quality and affordable health care, including sexual and
reproductive services.”129
The importance of a legally binding obligation to set health equity as a
policy objective cannot be underestimated. Economic and epidemiological
evidence, no matter how scientific, objective and technically sound, can
inform but cannot determine policy priorities.130 Priority setting is a function
of many factors with different capacities to influence health policy decisionmakers.131
Economic efficiency is one such factor. Cost-effectiveness studies are
regarded as potent ammunition to support expanded vaccination programs.132
Research on HPV vaccines demonstrates that even at costs somewhat higher
than traditional vaccines, HPV vaccination is a cost-effective measure even for
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the poorest countries.133 Such research is especially valuable given that
consensus among technical experts supported by or affiliated with
international agencies is influential in the field of immunization.134
Disease burden is also an important factor.135 Decision-makers may be
unaware of the burden of cervical cancer.136 Burden of disease that is
inadequately quantified, the case with many gynecological diseases in
developing countries, can adversely affect priority setting.137 Even where
disease burden is measured, “cervical cancer has still not received sufficient
attention in many countries, despite its high incidence, morbidity and
mortality.”138 Cervical cancer and HPV vaccines remain low on priority setting
agendas, which may be explained by value judgments of both the disease and
the persons burdened. Value judgment is among the highest-ranking factors
influencing priority setting.139
Priority setting is a government process through which the social
hierarchy is converted into unequal health resources. Value judgment within
priority setting tracks the social hierarchy. The health status and needs of
groups lower on the social hierarchy are accordingly judged of lesser social
value, warranting lower priority and fewer resources within the health system.
As Braveman astutely observes, “It would be disingenuous to suggest that the
policy-making process — which determines resource allocation — represents
the interests of all social groups equally.”140
The women who
disproportionately develop and die of cervical cancer are the very women who
have suffered from the lifelong effects of gender bias and low social status,
those with the least political and economic influence.141 Many sexual health
issues, including HPV infection and cervical cancer, are wrongly associated
with illicit sexual behavior and poor genital hygiene.142 These health issues in
consequence are undervalued by communities and neglected by the health
system.143 To combat in part this prejudice against sexual health, HPV
vaccines are referred to and promoted as vaccines against cancer rather than
HPV infection.

133
See, e.g., Sue J. Goldie et al., Health and Economic Outcomes of HPV 16, 18
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Health equity as a human right redefines the health status and needs of
disadvantaged social groups: how they are perceived and valued by decisionmakers. Government obligations, especially those of legally binding nature,
are factors that influence priority setting.144 The human rights to health and
equality legally obligate government to ensure that women’s health, especially
the prevention and treatment of diseases disproportionately affecting socially
disadvantaged women, receives an equitable share of resources. HPV
vaccines, as a remedy to cervical cancer inequity, may thus be revalued and
reprioritized within health systems.
B. The Obligation to Enact Measures to Ensure Health Equity as a
Policy Outcome
Policy objectives alone do not dictate policy outcomes. Policy objectives
stated in terms of efficiency and improvement of societal average health status
may, for example, inadvertently reduce social health disparities. This is true
where the health policy concerns diseases and interventions that
disproportionately affect disadvantaged social groups, such as infectious
diseases and immunization programs.145 These health equity effects require,
however, that disadvantaged social groups with the greatest need derive the
greatest benefit of intervention.146 Absent a concerted effort or legal
obligation to ensure health equity in policy outcomes, the inverse equity
hypothesis predicts the likely benefit distribution.147
The inverse equity hypothesis is a corollary to the inverse care law, which
maintains that “the availability of good medical care tends to vary inversely
with the need for it in the population served.”148 According to the inverse
equity hypothesis, advantaged social groups with the most resources will
derive the initial and maximum benefit of any new public health intervention,
increasing social health disparities.149 Health equity will only improve when
advantaged social groups reach minimum achievable levels of morbidity and
mortality, beyond which there are unlikely to be substantial further
improvements, their capacity to benefit exhausted.150 Only when
disadvantaged social groups gain access to the intervention in the final stages
towards universal coverage will social health disparities decrease.151
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The inverse equity hypothesis is expected to prove true in the case of HPV
vaccines and cervical cancer.152 The introduction of new vaccines, generally,
begins in the private and public sectors of developed countries, progresses to
the relatively small private sectors of developing countries, and eventually
reaches the public sectors of these countries.153 The evidence to date indicates
that HPV vaccines have followed this course.
Although HPV vaccines are licensed in countries worldwide, they have yet
to be widely introduced into the public sectors in developing countries.154 The
vaccines are largely restricted to the private sector, and thus affordable only to
the economically advantaged. Several developed countries, in contrast, have
issued formal recommendations about the large-scale use of HPV vaccines in
immunization programs as well as national and public sector health
systems.155
It is expected that for some time access to HPV vaccines will track
underlying social position, increasing rather than decreasing cervical cancer
inequity. It can take nearly two decades from first licensure in a developed
country before new vaccines are introduced into the public sector of
developing countries.156 Without “mechanisms for accelerated introduction,
developing countries find themselves at the distal end of an introduction
cascade . . . with the public sectors of those countries lagging far behind in last
place.”157 This delay, requiring disadvantaged social groups to wait and be the
last to benefit from HPV vaccines, is itself inequitable.158
Advantaged and disadvantaged social groups moreover are unequally
situated with respect to need. Although individual-level risk factors may be
relatively similar across the social hierarchy, disparate access to conventional
screening programs creates a greater need for HPV vaccines among the
socially disadvantaged. Developed countries that have issued formal
recommendations on public sector use of HPV vaccines, it is noted, have
“cervical cancer screening programs with moderate or high population
coverage . . . and consequently, they have a relatively lower burden of cervical
cancer than many other countries with limited or no screening.”159 It is
inequitable that those with the least rather than greatest need receive the
initial and maximum benefit of HPV vaccination.160
For these reasons, it is of crucial importance that international human
rights law imposes health equity obligations of both objectives and outcomes.
The rights to health and equality require that government enact measures to
ensure health equity as a policy outcome.
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Article 12 of CESCR obligates government “to adopt appropriate
legislative, administrative, budgetary, judicial, promotional, and other
measures towards the full realization of the right to health.”161 Article 12 of
CEDAW requires similar measures to the extent of available resources to
ensure realization of women’s right to health.162 International human rights
law acknowledges, however, that the “appropriateness” of measures will not
always be self-evident and will vary from one jurisdiction to another.163
Government is thus obligated to demonstrate why the measures chosen are
considered the most “appropriate” under the circumstances.164 Article 12 of
CEDAW, for example, requires government to “demonstrate that health
legislation, plans and policies are based on . . . assessment of the health status
and needs of women in that country”165 in a way that recognizes the
“distinctive features and factors which differ for women in comparison to
men.”166
The rights to health and equality, in summary, obligate government to
adopt appropriate measures to ensure in outcome the equitable distribution of
and access to health facilities, goods and services. To ensure that HPV
vaccines are distributed and accessible to disadvantaged social groups, this
obligation requires government to account for and address the following
considerations: affordability, social and sexual norms, information and
education, and delivery systems.
Affordability is an essential component of equitable HPV vaccination
programs.167 Given the high price of HPV vaccines, if available only in the
private sector, disadvantaged social groups will be effectively denied access.
Advantaged social groups will take up opportunistic vaccination, increasing
social disparities in cervical cancer.168 To ensure equitable use, HPV vaccines
must be made available through publicly funded programs or systems.
International law recognizes that while resource constraints may “render
it impossible for a State to comply fully with its . . . [human rights]
obligations, it has the burden of justifying that every effort has nevertheless
been made to use all available resources at its disposal in order to satisfy, as a
matter of priority, the[se] obligations.”169 All available resources are defined
as “both the resources existing within a State and those available from the
international community through international co-operation and
assistance.”170 International financial mechanisms, such as the GAVI Alliance
and the Pan American Health Organization (“PAHO”) Revolving Fund, are
161
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therefore relevant to fulfilling human rights obligations.171 Government is
obligated “to take steps, individually and through international assistance and
co-operation, especially economic and technical, towards the full realization
. . . of the right to health.”172 The obligation to protect the right to health
further requires government “to take measures that prevent third parties from
interfering with article 12 guarantees” including economic accessibility.173
These measures may include negotiated pricing and subsidies from the
vaccine industry.
To ensure equitable health outcomes, HPV vaccination programs must
account for social norms, including sexual norms, relevant to vaccine demand
and utilization. This requirement is reflected under the right to equality,
which obligates government to ensure preventive health services are
acceptable, “delivered in a way that ensures that a woman gives her fully
informed consent . . . [and] sensitive to her needs and perspectives.” 174
As a vaccine against HPV, a sexually transmitted infection, it may be
wrongly assumed, including by health providers, that relative need for
vaccination is a consequence of individual-level factors, such as stigmatized
sexual and other social behaviors.175 Socially disadvantaged women may be
unwilling to associate themselves and their adolescent daughters with
stigmatized behaviors, thereby reducing demand for HPV vaccines.176 The
association of HPV vaccines with sexual health may also lead to fears,
especially among disadvantaged social groups subject to past coercive
government practices, that HPV vaccination is a form of sterilization or
fertility control.177
General Recommendation No. 24 recognizes that “[a]dolescent girls and
women in many countries lack adequate access to information and services
necessary to ensure sexual health.”178 Evidence on information and knowledge
respecting HPV infection, cervical cancer and HPV vaccines supports this
statement.179 The rights to health and equality obligate government to
promote education and develop information campaigns.180 A core obligation
under the right to health, as identified in General Comment No. 14, is the
provision of “education and access to information concerning the main health
problems in the community, including methods of preventing and controlling
them.”181 HPV vaccination programs must thus not only meet existing
171
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demand, but stimulate demand among disadvantaged social groups through
information and education about HPV infection, the purposes and benefits of
HPV vaccines, and sexual health more generally.182
Physical accessibility is an important consideration in delivery systems.
Community-based programs, as a complement to school-based delivery, may
be required to ensure that HPV vaccination coverage does not reflect social
disparities in school enrollment.183 The design and implementation of new
measures to reach adolescents for HPV vaccination may moreover strengthen
the delivery of adolescent sexual health services more broadly. 184 HPV
vaccination programs may thus function as part of a larger set of “allocate[d]
resources for programmes directed at adolescents for the prevention and
treatment of sexually transmitted diseases, including HIV/AIDS” as
recommended under the right to equality.185
This consideration leads to a final but important concern respecting HPV
vaccination programs and equitable health outcomes. HPV vaccines are not
substitutes for routine screening. Many women will not receive the vaccines,
which moreover, do not protect against infection with all high-risk HPV types.
HPV vaccines, most importantly, will not affect the cervical cancer risk of the
millions of women worldwide already infected with HPV. With the adoption
of HPV vaccines, government is thus obligated not to abandon alternative
measures to improve cervical cancer prevention, such as “technologically
appropriate, accessible and effective” screening methods.186 HPV vaccination
programs should be treated as one component of a cervical cancer prevention
strategy, and integrated within a comprehensive delivery structure for sexual
and reproductive health care.
Measures to realize health equity as a human right must not be reduced to
narrow disease-specific interventions divorced from the health system and
broader determinants that drive social health disparities.187 HPV vaccines can
and should be implemented as a measure to strengthen health systems, and
thereby improve the situation of the disadvantaged across health outcomes.
Government obligations respecting health equity as a human right extend to
all levels of policy-making that affect social health disparities, from micro to
macro, from viral to societal.188

182

See Domingo et al., supra note 154, at M77.
Agosti et al., supra note 1, at 1908-09; Domingo et al., supra note 154, at M78; Jane
Harries et al., Preparing for HPV Vaccination in South Africa: Key Challenges and Opinions,
27 Vaccine 38, 41 (2009); Kane et al., supra note 152, at 135; Amy E. Pollack et al., Ensuring
Access to HPV Vaccines through Integrated Services: A Reproductive Health Perspective, 85
Bull. World Health Org. 57, 60 (2007).
184
Agosti & Goldie, supra note 1, at 1908-09; Pollack et al., supra note 168, at 60;
Winkler et al., supra note 125, at L75.
185
General Recommendation No. 24, supra note 54, ¶ 31(b).
186
Denny, supra note 43 at 1210.
187
Anne-Emanuelle Birn, Gates’s Grandest Challenge: Transcending Technology as
Public Health Ideology, 266 Lancet 514, 515 (2005).
188
See Nancy Krieger, Proximal, Distal, and the Politics of Causation: What’s Level Got
to Do with It?, 98 Am. J. Pub. Health 221, 227 (2008).
183

Electronic copy available at: https://ssrn.com/abstract=1483342

HUMAN RIGHTS IN HEALTH EQUITY

387

CONCLUSION
The concept of “child survival” is a “potent and galvanizing platform” that
mobilizes global public sentiment in support of early childhood immunization
programs.189 Health equity serves a similar function respecting cervical cancer
and access to HPV vaccines. The objective of this article is to translate health
equity from an ethical and political claim into a legal claim under
international human rights law. Health equity is a human right. Its empirical
and normative dimensions – government action and distributive justice – are
reflected in the human rights to health and equality. Social disparities in
cervical cancer, a health inequity, may thus be reconceived as a human rights
violation. Social health disparities are unjust because they result from
government action in violation of international human rights law.
International human rights law offers more than an additional claim of
injustice. It requires remedial action. Government is legally obligated to
account for and to remedy social health disparities. The obligations that flow
from health equity as a human right, broadly phrased, include the obligation
to act in pursuit of health equity as a policy objective, and the obligation to
enact measures to ensure health equity as a policy outcome.
International human rights law sets health equity as a policy objective to
be taken into account in resource allocation and program design. The
obligation to act in pursuit of health equity as a policy objective redefines the
health status and needs of disadvantaged social groups, how they are
perceived and valued, within priority setting. Government is legally obligated
to ensure that women’s health, especially the prevention and treatment of
diseases disproportionately affecting socially disadvantaged women, receives
an equitable share of resources. HPV vaccines, as a remedy to cervical cancer
inequity, may thus be revalued and reprioritized within health systems
worldwide.
Policy objectives alone, however, cannot guarantee policy outcomes.
Absent measures to ensure equitable distribution and access, advantaged
social groups will derive the initial and maximum benefit of HPV vaccines,
increasing rather than decreasing social disparities in cervical cancer. It is
therefore of crucial importance that international human rights law obligates
government to adopt appropriate measures to ensure HPV vaccines are
distributed and accessible to disadvantaged social groups.
Health inequity is not inevitable. There are many promising remedial
actions that can be taken.190 By situating new health interventions, such as
HPV vaccines, within a framework of legal rights and obligations, this article
seeks to strengthen the normative commitment to ensure these actions are
taken.
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